Conestoga Capital Advisors LLC Purchases New Holdings in Artivion, Inc. $AORT

Conestoga Capital Advisors LLC bought a new position in shares of Artivion, Inc. (NYSE:AORT) during the first quarter, according to its most recent filing with the SEC. The fund bought 1,175,410 shares of the company’s stock, valued at approximately $43,044,000. Conestoga Capital Advisors LLC owned 2.42% of Artivion at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in AORT. Vanguard Group Inc. lifted its stake in Artivion by 4.7% in the fourth quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock valued at $144,588,000 after purchasing an additional 141,030 shares during the last quarter. Morgan Stanley increased its position in Artivion by 0.8% in the fourth quarter. Morgan Stanley now owns 2,256,742 shares of the company’s stock worth $102,930,000 after buying an additional 18,248 shares during the last quarter. State Street Corp raised its stake in shares of Artivion by 2.9% in the fourth quarter. State Street Corp now owns 1,584,920 shares of the company’s stock valued at $72,288,000 after buying an additional 44,641 shares during the period. Fred Alger Management LLC raised its stake in shares of Artivion by 4.2% in the fourth quarter. Fred Alger Management LLC now owns 1,372,572 shares of the company’s stock valued at $62,603,000 after buying an additional 55,322 shares during the period. Finally, Invesco Ltd. lifted its position in shares of Artivion by 211.9% during the 4th quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock valued at $50,228,000 after buying an additional 748,119 shares during the last quarter. Institutional investors own 86.37% of the company’s stock.

Insider Activity

In other news, SVP Andrew M. Green sold 44,001 shares of the company’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $20.70, for a total value of $910,820.70. Following the completion of the sale, the senior vice president owned 60,259 shares of the company’s stock, valued at approximately $1,247,361.30. This represents a 42.20% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.30% of the company’s stock.

Artivion Price Performance

Shares of NYSE:AORT opened at $23.60 on Thursday. The company has a 50 day moving average of $25.11 and a 200 day moving average of $34.82. The company has a current ratio of 3.86, a quick ratio of 2.80 and a debt-to-equity ratio of 0.48. The stock has a market cap of $1.15 billion, a P/E ratio of 98.34 and a beta of 1.26. Artivion, Inc. has a 12 month low of $19.16 and a 12 month high of $48.25.

Analysts Set New Price Targets

A number of equities analysts have weighed in on AORT shares. Needham & Company LLC cut their target price on shares of Artivion from $58.00 to $44.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Stifel Nicolaus set a $45.00 price objective on shares of Artivion in a report on Monday, June 1st. Wall Street Zen lowered shares of Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Citizens Jmp lowered their target price on shares of Artivion from $53.00 to $48.00 and set a “market outperform” rating on the stock in a report on Friday, May 8th. Finally, LADENBURG THALM/SH SH upgraded Artivion from a “neutral” rating to a “buy” rating and set a $42.00 target price on the stock in a research report on Friday, April 10th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $44.17.

Artivion Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.